Trial · NCT04682639
Results by group39
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 39
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 | Experimental: Etrasimod 2 mg | -58.4 | Inter-Quartile Range -86.21 to -26.25 | Percent change | |
| Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 | Experimental: Etrasimod 1 mg | -39.4 | Inter-Quartile Range -71.08 to 78.95 | Percent change | |
| Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 | Placebo Then Etrasimod Any Dose | -21.5 | Inter-Quartile Range -57.20 to 55.42 | Percent change | |
| Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16 | Experimental: Etrasimod 2 mg | -17.11 | Standard Error 2.247 | Units on a scale | |
| Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16 | Experimental: Etrasimod 1 mg | -14.78 | Standard Error 2.166 | Units on a scale | |
| Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16 | Placebo Then Etrasimod Any Dose | -19.49 | Standard Error 2.602 | Units on a scale | |
| Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 | Experimental: Etrasimod 2 mg | -46.3 | Standard Error 17.46 | eos/hpf | |
| Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 | Experimental: Etrasimod 1 mg | -5.7 | Standard Error 16.99 | eos/hpf | |
| Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16 | Placebo Then Etrasimod Any Dose | 8.3 | Standard Error 22.37 | eos/hpf | |
| Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16 | Experimental: Etrasimod 2 mg | 22.0 | Percentage of participants | ||
| Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16 | Experimental: Etrasimod 1 mg | 12.8 | Percentage of participants | ||
| Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16 | Placebo Then Etrasimod Any Dose | 0 | Percentage of participants | ||
| Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16 | Experimental: Etrasimod 2 mg | 12.2 | Percentage of participants | ||
| Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16 | Experimental: Etrasimod 1 mg | 7.7 | Percentage of participants | ||
| Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16 | Placebo Then Etrasimod Any Dose | 0 | Percentage of participants | ||
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Maximum Severity During 24 Week Double Blind Treatment Period | Experimental: Etrasimod 2 mg | TEAE: Grade 1 | 19 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Maximum Severity During 24 Week Double Blind Treatment Period | Experimental: Etrasimod 1 mg | TEAE: Grade 1 | 15 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Maximum Severity During 24 Week Double Blind Treatment Period | Placebo Then Etrasimod Any Dose | TEAE: Grade 1 | 8 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Maximum Severity During 24 Week Double Blind Treatment Period | Experimental: Etrasimod 2 mg | TEAE: Grade 2 | 9 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Maximum Severity During 24 Week Double Blind Treatment Period | Experimental: Etrasimod 1 mg | TEAE: Grade 2 | 12 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04682639/results